Atopic Dermatitis

By MMIT

MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

MMIT

MMIT

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today